Section Arrow
NMRA.NASDAQ
- Neumora Therapeutics
Quotes are at least 15-min delayed:2025/08/30 23:16 EDT
Regular Hours
Last
 1.73
-0.03 (-1.70%)
Day High 
1.7597 
Prev. Close
1.76 
1-M High
2.35 
Volume 
236.54K 
Bid
1.7
Ask
1.72
Day Low
1.71 
Open
1.75 
1-M Low
1.39 
Market Cap 
285.02M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.66 
20-SMA 1.61 
50-SMA 1.45 
52-W High 17.1874 
52-W Low 0.611 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.57/-1.10
Enterprise Value
285.02M
Balance Sheet
Book Value Per Share
1.13
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CARMCarisma Therapeutics0.215-0.013-5.70%-- 
TNFATNF Pharmaceuticals Inc.0.0483-0.0133-21.59%-- 
ADAPAdaptimmune Therapeutics plc0.0589-0.01-14.51%-- 
SRPTSarepta Therapeutics18.2-0.14-0.76%15.76PE
OTLKOutlook Therapeutics0.8512-0.2388-21.91%0.58PE
Quotes are at least 15-min delayed:2025/08/30 23:16 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.